In This Article
Families exploring regenerative medicine often encounter the terms “Dezawa Muse cells,” “Muse stem cells” and “Muse cell therapy.” These searches reflect interest in a developing area of cell research associated with Professor Mari Dezawa and colleagues at Tohoku University in Japan.
Muse cells have attracted attention because of their reported biological properties and early clinical findings. Understanding what has been studied—and what remains uncertain—is essential when evaluating treatment claims.
What Are Muse Cells?
Muse stands for multilineage-differentiating stress-enduring cells.
In a landmark 2010 study, researchers described a population of cells within adult human mesenchymal cell populations that could withstand stressful conditions and develop characteristics of several cell types.
The research included laboratory experiments and animal studies. These findings helped establish the scientific basis for further investigation; they did not establish a treatment for every condition involving tissue damage. Original research published in PNAS
Who Is Professor Mari Dezawa?
Professor Mari Dezawa is a researcher at Tohoku University whose team contributed to the discovery and study of Muse cells.
Tohoku University describes ongoing research into Muse-cell biology and potential applications in neurological injury, including ischemic stroke. The phrase “Dezawa Muse cells” connects this field with her research, but the name alone does not establish the quality or effectiveness of a particular commercial product. Tohoku University research
Why Are Researchers Interested in Muse Cells?
Potential to Develop Into Different Cell Types
The original research reported characteristics associated with multiple cell lineages. This raised questions about whether Muse cells might contribute to tissue repair under particular conditions.
Stress Tolerance
Their ability to survive experimental stress is part of the reason they were identified and named.
Tissue-Repair Research
Laboratory and animal experiments have investigated how these cells behave in damaged tissue. Those results provide reasons to conduct clinical studies, but they cannot predict an individual patient’s response. Original Muse-cell study
These are potential biological advantages under investigation, rather than guaranteed clinical benefits.
What Have Muse Cell Clinical Trials Found?
Research in Adults After Ischemic Stroke
A small randomized, placebo-controlled trial studied CL2020, a specific donor-derived Muse-cell product, in adults following ischemic stroke. Thirty-five participants received treatment: 25 received CL2020 and 10 received placebo.
The researchers reported encouraging functional findings, although results were not statistically significant across all comparisons. Safety was a central focus, and adverse events were recorded, including a case of status epilepticus in the treated group.
The study supports further investigation. It does not establish that every product marketed as Muse cells will have the same effects, or that results in adults shortly after stroke apply to children with longstanding neurological conditions. Published CL2020 stroke trial
Research in Newborns With Hypoxic-Ischemic Encephalopathy
The SHIELD phase 1 study investigated CL2020 in nine newborns with moderate-to-severe hypoxic-ischemic encephalopathy who had received therapeutic hypothermia.
The study focused on safety and tolerability. Its small size and lack of a randomized comparison group mean it cannot establish treatment effectiveness. The authors called for a follow-up randomized controlled study. Published SHIELD trial
What Does This Mean for Muse Cells and Cerebral Palsy?
Research involving newborn brain injury is not the same as evidence for treating established cerebral palsy in an older child.
Likewise, an adult stroke study cannot establish benefits for autism, developmental delay or every form of neurological injury. These populations differ in diagnosis, age, timing of injury and treatment goals.
When reading about Muse cells for cerebral palsy, ask whether the cited study actually involved children with cerebral palsy—and whether it used the same product and protocol being proposed.
Are All Muse Cell Products the Same?
A study evaluates a particular preparation, manufacturing process, dose, route of administration and patient population.
CL2020 findings therefore should not be presented as proof that an unrelated preparation is equivalent. Families should request product-specific evidence rather than relying on the general phrase “Muse stem cells.”
There is also an important development-history detail: Mitsubishi Chemical Group announced in February 2023 that it would discontinue CL2020 development, citing clinical-development considerations, commercialization timelines and business strategy. That announcement concerns a specific development program; it does not settle every scientific question about Muse cells. Developer’s announcement
Questions to Ask Before Considering a Cell-Based Intervention
A clear discussion should address:
What is the exact product, and who manufactures it?
What human studies support its use for this diagnosis and age group?
Is the proposed treatment identical to the studied preparation?
What is its regulatory status for this use in the country where it will be administered?
What risks and uncertainties are known?
How will adverse events and long-term outcomes be monitored?
Is this part of a registered clinical trial?
What standard care and rehabilitation should continue?
Research participation, commercial availability and regulatory approval are different matters. Ask for documentation explaining which applies.
Frequently Asked Questions
Are Muse cells the same as all mesenchymal stem cells?
No. Muse cells were described as a particular population within mesenchymal cell populations. Evidence about one cell preparation should not automatically be applied to another. Original discovery study
Have Muse cells been proven to cure cerebral palsy?
The stroke and newborn HIE studies discussed here do not establish a cure for cerebral palsy.
Does “non-tumorigenic” mean risk-free?
No. A biological finding in a particular experimental setting does not establish that every preparation is safe in every patient. Clinical safety requires product-specific evidence and follow-up.
Does this article mean Muse-cell treatment is available at HOPE AMC?
No. This article explains research. It does not announce a Muse-cell treatment service or establish approval or availability at HOPE AMC.
Bring Research Questions Into Your Child’s Care Discussion
New research can raise important questions about future care. Bring the original study or proposed treatment details to your child’s clinical team so the discussion can focus on the actual evidence and your child’s needs.
Contact HOPE AMC to discuss your child’s existing assessment and rehabilitation plan.
This article is educational and does not recommend an experimental cell-based intervention.
Concerned about your child’s development?
Book an assessment and take the first step towards the right care for your child.
